Open Access iconOpen Access

ARTICLE

crossmark

GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

GUOQIANG HOU1,2,#, XINHANG XU2,#, WEIXING HU1,*

1 Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China

* Corresponding Author: WEIXING HU. Email: email
# Guoqiang Hou and Xinhang Xu contributed equally

Oncology Research 2024, 32(4), 727-736. https://doi.org/10.32604/or.2023.043391

Abstract

Primary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable disease, and the median survival time of patients with GBM is shorter than 15 months. Thus, molecular mechanisms of GBM characteristic invasive growth need to be clarified to improve the poor prognosis. Glutamate ionotropic receptor kainate type subunit 1 (GRIK1) is essential for brain function and is involved in many mental and neurological diseases. However, GRIK1’s pathogenic roles and mechanisms in GBM are still unknown. Single-nuclear RNA sequencing of primary and recurrent GBM samples revealed that GRIK1 expression was noticeably higher in the recurrent samples. Moreover, immunohistochemical staining of an array of GBM samples showed that high levels of GRIK1 correlated with poor prognosis of GBM, consistent with The Cancer Genome Atlas database. Knockdown of GRIK1 retarded GBM cells growth, migration, and invasion. Taken together, these findings show that GRIK1 is a unique and important component in the development of GBM and may be considered as a biomarker for the diagnosis and therapy in individuals with GBM.

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
HOU, G., XU, X., HU, W. (2024). GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis. Oncology Research, 32(4), 727-736. https://doi.org/10.32604/or.2023.043391
Vancouver Style
HOU G, XU X, HU W. GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis. Oncol Res. 2024;32(4):727-736 https://doi.org/10.32604/or.2023.043391
IEEE Style
G. HOU, X. XU, and W. HU "GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis," Oncol. Res., vol. 32, no. 4, pp. 727-736. 2024. https://doi.org/10.32604/or.2023.043391



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 688

    View

  • 154

    Download

  • 0

    Like

Share Link